FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3166606476> ?p ?o ?g. }

• W3166606476 abstract "Background Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment, up to 70% of individuals with active epilepsy have the potential to become seizure‐free and go into long‐term remission shortly after starting drug therapy, the majority of which may be able to achieve remission with a single antiepileptic drug (AED). The correct choice of first‐line antiepileptic therapy for individuals with newly diagnosed seizures is of great importance. It is important that the choice of AED for an individual is based on the highest‐quality evidence available regarding the potential benefits and harms of various treatments. It is also important to compare the efficacy and tolerability of AEDs appropriate to given seizure types. Topiramate and carbamazepine are commonly used AEDs. Performing a synthesis of the evidence from existing trials will increase the precision of results of outcomes relating to efficacy and tolerability, and may help inform a choice between the two drugs. Objectives To assess the effects of topiramate monotherapy versus carbamazepine monotherapy for epilepsy in people with partial‐onset seizures (simple or complex partial and secondarily generalised) or generalised onset tonic‐clonic seizures (with or without other generalised seizure types). Search methods We searched the Cochrane Epilepsy Group Specialized Register (14 April 2016), the Cochrane Central Register of Controlled Trials (CENTRAL) (14 April 2016) and MEDLINE (Ovid, 1946 to 14 April 2016). We imposed no language restrictions. We also contacted pharmaceutical companies and trial investigators. Selection criteria Randomised controlled trials in children or adults with partial‐onset seizures or generalised‐onset tonic‐clonic seizures with or without other generalised seizure types with a comparison of monotherapy with either topiramate or carbamazepine. Data collection and analysis This was an individual participant data (IPD) review. Our primary outcome was 'time to withdrawal of allocated treatment’, and our secondary outcomes were 'time to first seizure post randomisation’, 'time to 6‐month remission, 'time to 12‐month remission’ and incidence of adverse events. We used Cox proportional hazards regression models to obtain trial‐specific estimates of hazard ratios (HRs) with 95% confidence intervals (CIs), and used the generic inverse variance method to obtain the overall pooled HRs and 95% CIs. Main results IPD were available for 1151 of 1239 eligible individuals from two of three eligible studies (93% of the potential data). A small proportion of individuals recruited into these trials had 'unclassified seizures;' for analysis purposes, these individuals are grouped with those with generalised onset seizures. For remission outcomes, a HR < 1 indicated an advantage for carbamazepine, and for first seizure and withdrawal outcomes, a HR < 1 indicated an advantage for topiramate. The main overall results, given as pooled HR adjusted for seizure type (95% CI) were: for time to withdrawal of allocated treatment 1.16 (0.98 to 1.38); time to first seizure 1.11 (0.96 to 1.29); and time to 6‐month remission 0.88 (0.76 to 1.01). There were no statistically significant differences between the drugs. A statistically significant advantage for carbamazepine was shown for time to 12‐month remission: 0.84 (0.71 to 1.00). The results of this review are applicable mainly to individuals with partial‐onset seizures; 85% of included individuals experienced seizures of this type at baseline. For individuals with partial‐onset seizures, a statistically significant advantage for carbamazepine was shown for time to withdrawal of allocated treatment (HR 1.20, 95% CI 1.00 to 1.45) and time to 12‐month remission (HR 0.84, 95% CI 0.71 to 1.00). No statistically significant differences were apparent between the drugs for other outcomes and for the limited number of individuals with generalised‐onset tonic‐clonic seizures with or without other generalised seizure types or unclassified seizures. The most commonly reported adverse events with both drugs were drowsiness or fatigue, ‘pins and needles’ (tingling sensation), headache, gastrointestinal disturbance and anxiety or depression The rate of adverse events was similar across the two drugs. We judged the methodological quality of the included trials generally to be good; however, there was some evidence that the open‐label design of the larger of the two trials may have influenced the withdrawal rate from the trial. Hence, we judged the evidence for the primary outcome of treatment withdrawal to be moderate for individuals with partial‐onset seizures and low for individuals with generalised‐onset seizures. For efficacy outcomes (first seizure, remission), we judged the evidence from this review to be high for individuals with partial‐onset seizures and moderate for individuals with generalised‐onset or unclassified seizures. Authors' conclusions For individuals with partial‐onset seizures, there is evidence that carbamazepine is less likely to be withdrawn and that 12‐month remission will be achieved earlier than with topiramate. No differences were found between the drugs in terms of the outcomes measured in the review for individuals with generalised tonic‐clonic seizures with or without other seizure types or unclassified epilepsy; however, we encourage caution in the interpretation of these results due to the small numbers of participants with these seizure types. We recommend that future trials should be designed to the highest quality possible and take into consideration masking, choice of population, classification of seizure type, duration of follow‐up, choice of outcomes and analysis, and presentation of results." @default.
• W3166606476 created "2021-06-22" @default.
• W3166606476 creator A5005069325 @default.
• W3166606476 creator A5046267575 @default.
• W3166606476 creator A5048955034 @default.
• W3166606476 creator A5079108186 @default.
• W3166606476 date "2016-12-06" @default.
• W3166606476 modified "2023-09-24" @default.
• W3166606476 title "Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review" @default.
• W3166606476 cites W1491157696 @default.
• W3166606476 cites W1804711980 @default.
• W3166606476 cites W1917794385 @default.
• W3166606476 cites W1965295928 @default.
• W3166606476 cites W1967986271 @default.
• W3166606476 cites W1974311184 @default.
• W3166606476 cites W1974809694 @default.
• W3166606476 cites W1979742136 @default.
• W3166606476 cites W1994572997 @default.
• W3166606476 cites W2027759517 @default.
• W3166606476 cites W2031306229 @default.
• W3166606476 cites W2034278159 @default.
• W3166606476 cites W2034566726 @default.
• W3166606476 cites W2035632263 @default.
• W3166606476 cites W2046391772 @default.
• W3166606476 cites W2056985895 @default.
• W3166606476 cites W2058147010 @default.
• W3166606476 cites W2075642745 @default.
• W3166606476 cites W2076472832 @default.
• W3166606476 cites W2076993158 @default.
• W3166606476 cites W2086001349 @default.
• W3166606476 cites W2088095316 @default.
• W3166606476 cites W2093695045 @default.
• W3166606476 cites W2098082628 @default.
• W3166606476 cites W2103024352 @default.
• W3166606476 cites W2106277748 @default.
• W3166606476 cites W2114138473 @default.
• W3166606476 cites W2115247476 @default.
• W3166606476 cites W2116130425 @default.
• W3166606476 cites W2119186079 @default.
• W3166606476 cites W2119843181 @default.
• W3166606476 cites W2125435699 @default.
• W3166606476 cites W2138521331 @default.
• W3166606476 cites W2139593954 @default.
• W3166606476 cites W2139992285 @default.
• W3166606476 cites W2147974822 @default.
• W3166606476 cites W2156420184 @default.
• W3166606476 cites W2168915562 @default.
• W3166606476 cites W2171069034 @default.
• W3166606476 cites W2336817565 @default.
• W3166606476 cites W2551860952 @default.
• W3166606476 cites W4231921691 @default.
• W3166606476 cites W4238361226 @default.
• W3166606476 cites W4241136696 @default.
• W3166606476 cites W4246072528 @default.
• W3166606476 cites W4251662319 @default.
• W3166606476 cites W641823132 @default.
• W3166606476 doi "https://doi.org/10.1002/14651858.cd012065.pub2" @default.
• W3166606476 hasPublicationYear "2016" @default.
• W3166606476 type Work @default.
• W3166606476 sameAs 3166606476 @default.
• W3166606476 citedByCount "8" @default.
• W3166606476 countsByYear W31666064762017 @default.
• W3166606476 countsByYear W31666064762018 @default.
• W3166606476 countsByYear W31666064762019 @default.
• W3166606476 crossrefType "journal-article" @default.
• W3166606476 hasAuthorship W3166606476A5005069325 @default.
• W3166606476 hasAuthorship W3166606476A5046267575 @default.
• W3166606476 hasAuthorship W3166606476A5048955034 @default.
• W3166606476 hasAuthorship W3166606476A5079108186 @default.
• W3166606476 hasBestOaLocation W31666064762 @default.
• W3166606476 hasConcept C118552586 @default.
• W3166606476 hasConcept C187212893 @default.
• W3166606476 hasConcept C197934379 @default.
• W3166606476 hasConcept C2775858608 @default.
• W3166606476 hasConcept C2777683783 @default.
• W3166606476 hasConcept C2778186239 @default.
• W3166606476 hasConcept C2778375690 @default.
• W3166606476 hasConcept C2778802184 @default.
• W3166606476 hasConcept C2779253243 @default.
• W3166606476 hasConcept C2780874087 @default.
• W3166606476 hasConcept C71924100 @default.
• W3166606476 hasConcept C98274493 @default.
• W3166606476 hasConceptScore W3166606476C118552586 @default.
• W3166606476 hasConceptScore W3166606476C187212893 @default.
• W3166606476 hasConceptScore W3166606476C197934379 @default.
• W3166606476 hasConceptScore W3166606476C2775858608 @default.
• W3166606476 hasConceptScore W3166606476C2777683783 @default.
• W3166606476 hasConceptScore W3166606476C2778186239 @default.
• W3166606476 hasConceptScore W3166606476C2778375690 @default.
• W3166606476 hasConceptScore W3166606476C2778802184 @default.
• W3166606476 hasConceptScore W3166606476C2779253243 @default.
• W3166606476 hasConceptScore W3166606476C2780874087 @default.
• W3166606476 hasConceptScore W3166606476C71924100 @default.
• W3166606476 hasConceptScore W3166606476C98274493 @default.
• W3166606476 hasLocation W31666064761 @default.
• W3166606476 hasLocation W31666064762 @default.
• W3166606476 hasLocation W31666064763 @default.
• W3166606476 hasOpenAccess W3166606476 @default.
• W3166606476 hasPrimaryLocation W31666064761 @default.
• W3166606476 hasRelatedWork W2035236874 @default.

• next